SCHEMBL3486501

SCHEMBL3486501

C[C@@H](C[N+](=O)[O-])c1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.51
ADAM17 P78536 1/20 0.51
TAAR1 Q96RJ0 3/20 0.48
TRPA1 O75762 3/20 0.47
MEN1 O00255 1/20 0.46
POLB P06746 1/20 0.46
KMT2A Q03164 1/20 0.46
KDM4E B2RXH2 1/20 0.46
MAPT P10636 1/20 0.46
MAPK1 P28482 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
APOBEC3G Q9HC16 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
CPA1 P15085 3/20 0.44
AOC3 Q16853 2/20 0.44
CNR1 P21554 1/20 0.43
CNR2 P34972 1/20 0.43
RIPK1 Q13546 1/20 0.42
GSR P00390 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27862778 1.00 NPC1 (0.51) NPC1ADAM17TAAR1TRPA1MEN1
SCHEMBL1985442 1.00 NPC1 (0.51) NPC1ADAM17TAAR1TRPA1MEN1
SCHEMBL1984032 0.82 ALDH1A1 (0.50) MEN1KMT2AKDM4EMAPTMAPK1
SCHEMBL17466741 0.82 ALDH1A1 (0.50) MEN1KMT2AKDM4EMAPTMAPK1
SCHEMBL9202581 0.80 NPC1 (0.56) NPC1ADAM17MEN1POLBKMT2A
SCHEMBL17466748 0.80 ALDH1A1 (0.49) MEN1POLBKMT2AKDM4EMAPT
SCHEMBL1987865 0.80 TAAR1 (0.52) NPC1ADAM17TAAR1MEN1POLB
SCHEMBL1983437 0.80 ALDH1A1 (0.49) MEN1POLBKMT2AKDM4EMAPT
SCHEMBL5690104 0.80 NPC1 (0.49) NPC1ADAM17MEN1POLBKMT2A
SCHEMBL8586940 0.80 ALDH1A1 (0.43) NPC1ADAM17MEN1POLBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9744528-B2 Metallorganocatalysis for asymmetric transformations RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2017-08-29 US disclosed
US-9744528-B2 Metallorganocatalysis for asymmetric transformations RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2017-08-29 US disclosed
US-20160023198-A1 Metallorganocatalysis For Asymmetric Transformations Rutgars, The State University of New Jersey (US) 2016-01-28 US disclosed
US-20160023198-A1 Metallorganocatalysis For Asymmetric Transformations Rutgars, The State University of New Jersey (US) 2016-01-28 US disclosed
US-8313923-B2 Process for enzymatic reduction of alkene derivatives BASF SE (DE) 2012-11-20 US disclosed
US-20100035315-A1 Any alpha-beta unsaturated ketone, aldehyde, carboxy or ester, or vinyl-unsaturated nitro compound to corresponding saturated compound; for example, citral to citronellal or 3-methylcyclohexenone to 3-methylcyclohexanone, using biocatalyst; stereospecific and efficient BASF SE (DE) 2010-02-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160023198-A1 Metallorganocatalysis For Asymmetric Transformations SOD1, AOC3, CBR1 NPC1 3226/4885ADAM17 4494/4885TAAR1 475/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.